Nexmed - Best Pharma Stocks of 2007
Company: Nexmed
Starting stock price: $0.72
Ending stock price: $1.42
Percent Change: 97.22%
Details: Nexmed is using NexACT--it's transdermal drug delivery technology--to create therapies that can be delivered directly through the skin. The company is developing treatments for sexual disorders and nail fungus. In 2007 Nexmed completed patient enrollment in two Phase III studies for it's anti-fungal product, and filed an NDA for an erectile dysfunction treatment.
More News:
NexMed taps Berman as new CEO. Report
More stories about Nexmed
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
